Published in Eur Arch Psychiatry Clin Neurosci on February 04, 2009
Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One (2013) 1.59
Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry (2012) 0.95
Reduced prefrontal gyrification in obsessive-compulsive disorder. Eur Arch Psychiatry Clin Neurosci (2010) 0.94
Cannabis use and cognition in schizophrenia. Front Hum Neurosci (2009) 0.91
Auditory mismatch negativity deficits in long-term heavy cannabis users. Eur Arch Psychiatry Clin Neurosci (2010) 0.88
Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. Eur Arch Psychiatry Clin Neurosci (2012) 0.88
Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci (2013) 0.84
Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies. Curr Pharm Des (2012) 0.84
An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use. Front Psychiatry (2012) 0.77
MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse. Psychol Med (2012) 0.77
Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. J Psychiatry Neurosci (2015) 0.77
The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability. Front Psychiatry (2014) 0.77
A new depression scale designed to be sensitive to change. Br J Psychiatry (1979) 36.40
Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA (1990) 17.70
A review of MRI findings in schizophrenia. Schizophr Res (2001) 8.95
Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry (2002) 5.25
Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry (2000) 4.84
Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. N Engl J Med (1992) 4.54
Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry (1992) 3.93
Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging. Neurology (1992) 3.87
Decreased gray matter concentration in the insular, orbitofrontal, cingulate, and temporal cortices of cocaine patients. Biol Psychiatry (2002) 3.22
Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Arch Gen Psychiatry (1998) 2.92
Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ (2002) 2.74
Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. Am J Psychiatry (1990) 2.41
A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry (1998) 2.24
Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry (2008) 2.20
Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry (1999) 2.09
Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry (1994) 2.06
Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry (1991) 1.88
Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull (1990) 1.84
Dual diagnosis: a review of etiological theories. Addict Behav (1999) 1.80
Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend (2005) 1.71
Reduced cerebral grey matter observed in alcoholics using magnetic resonance imaging. Alcohol Clin Exp Res (1991) 1.71
Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry (2002) 1.68
Temporolimbic volume reductions in schizophrenia. Arch Gen Psychiatry (2000) 1.66
Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis (2000) 1.63
Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in central London. Br J Psychiatry (2001) 1.62
Studies of individuals with schizophrenia never treated with antipsychotic medications: a review. Schizophr Res (2002) 1.42
Schizophrenia: the fundamental questions. Brain Res Brain Res Rev (2000) 1.40
Substance misuse, psychiatric disorder and violent and disturbed behaviour. Br J Psychiatry (2000) 1.36
Decreased caudate volume in neuroleptic-naive psychotic patients. Am J Psychiatry (1998) 1.35
Thalamic volumes in patients with first-episode schizophrenia. Am J Psychiatry (2001) 1.30
Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res (2001) 1.29
Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci (1999) 1.27
Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport (2000) 1.27
Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull (1997) 1.26
Decreased frontal white-matter volume in chronic substance abuse. Int J Neuropsychopharmacol (2005) 1.20
Brain neuroimaging in cannabis use: a review. J Neuropsychiatry Clin Neurosci (2006) 1.18
Lack of hippocampal volume change in long-term heavy cannabis users. Am J Addict (2005) 1.17
Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia. Am J Psychiatry (2003) 1.14
Volume of the cingulate and outcome in schizophrenia. Schizophr Res (2005) 1.13
Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. J Clin Psychiatry (1991) 1.12
Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand (1992) 1.09
Precipitation and determination of the onset and course of schizophrenia by substance abuse--a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res (2002) 1.06
Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res (1996) 1.06
Psychosocial approaches to dual diagnosis. Schizophr Bull (2000) 1.05
Drug and alcohol problems amongst individuals with severe mental health problems in an inner city area of the UK. Soc Psychiatry Psychiatr Epidemiol (2001) 1.05
Compounded brain volume deficits in schizophrenia-alcoholism comorbidity. Arch Gen Psychiatry (2003) 1.04
Reliability and validity of the German version of the European Addiction Severity Index (EuropASI). J Stud Alcohol (2000) 1.04
Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci (2002) 1.03
Significance of cocaine history in schizophrenia. J Nerv Ment Dis (1990) 0.99
Schizophrenia, alcohol abuse, and violent behavior: a 26-year followup study of an unselected birth cohort. Schizophr Bull (1998) 0.99
Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci (1993) 0.99
Post-mortem volume measurements of limbic system and basal ganglia structures in chronic schizophrenics. Initial results from a new brain collection. Schizophr Res (1991) 0.96
Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol Med (1998) 0.93
Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br J Psychiatry (2007) 0.93
A volumetric MRI study of the entorhinal cortex in first episode neuroleptic-naive schizophrenia. Biol Psychiatry (2002) 0.91
Correlates of patterns of substance abuse among patients with schizophrenia. Hosp Community Psychiatry (1993) 0.88
Psychopathology in dual diagnosis and non-addicted schizophrenics--are there differences? Eur Arch Psychiatry Clin Neurosci (2001) 0.88
Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci (2006) 0.86
Effect of substance misuse in early psychosis. Br J Psychiatry Suppl (1998) 0.85
Dorsolateral prefrontal and superior temporal volume deficits in first-episode psychoses that evolve into schizophrenia. Eur Arch Psychiatry Clin Neurosci (2005) 0.85
Cannabis and brain morphology in recent-onset schizophrenia. Schizophr Res (2004) 0.84
Magnetic resonance imaging of the thalamus in first-episode psychosis. Am J Psychiatry (2001) 0.83
Clinical effects of recent cocaine use on patients with acute schizophrenia. Am J Psychiatry (1995) 0.79
Brain morphological abnormality in schizophrenia is independent of country of origin. Acta Psychiatr Scand (2003) 0.77
Tardive dyskinesia in psychiatric patients with substance use disorders. Am J Drug Alcohol Abuse (1990) 0.77
Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med (2006) 4.16
Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry (2010) 3.42
Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. Br J Psychiatry (2005) 2.84
microRNA-34c is a novel target to treat dementias. EMBO J (2011) 2.44
Fear is only as deep as the mind allows: a coordinate-based meta-analysis of neuroimaging studies on the regulation of negative affect. Neuroimage (2011) 2.02
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry (2012) 1.69
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry (2009) 1.64
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry (2012) 1.55
Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross-sectional study. Biol Psychiatry (2012) 1.53
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry (2010) 1.45
The role of the human ventral striatum and the medial orbitofrontal cortex in the representation of reward magnitude - an activation likelihood estimation meta-analysis of neuroimaging studies of passive reward expectancy and outcome processing. Neuropsychologia (2012) 1.44
Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. Exp Gerontol (2005) 1.39
[The confused patient]. MMW Fortschr Med (2014) 1.38
A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric family study of the parahippocampal gyrus. Schizophr Bull (2003) 1.34
Effects of antipsychotics on brain structure. Curr Opin Psychiatry (2006) 1.33
Functional neuroimaging of reward processing and decision-making: a review of aberrant motivational and affective processing in addiction and mood disorders. Brain Res Rev (2008) 1.25
Genetic load on amygdala hypofunction during sadness in nonaffected brothers of schizophrenia patients. Am J Psychiatry (2004) 1.24
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci (2013) 1.24
Cognitive effects of high-frequency repetitive transcranial magnetic stimulation: a systematic review. J Neural Transm (Vienna) (2009) 1.22
Common and distinct neural correlates of emotional processing in Bipolar Disorder and Major Depressive Disorder: a voxel-based meta-analysis of functional magnetic resonance imaging studies. Eur Neuropsychopharmacol (2011) 1.21
Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry (2007) 1.19
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol (2009) 1.19
Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. Cereb Cortex (2002) 1.18
Schizophrenia as a disorder of disconnectivity. Eur Arch Psychiatry Clin Neurosci (2011) 1.18
Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. Arch Gen Psychiatry (2010) 1.17
Disturbed functional connectivity within brain networks subserving domain-specific subcomponents of working memory in schizophrenia: relation to performance and clinical symptoms. J Psychiatr Res (2009) 1.16
Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord (2005) 1.12
Hippocampal complexin proteins and cognitive dysfunction in schizophrenia. Arch Gen Psychiatry (2005) 1.11
The effects of physical exercise in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci (2013) 1.11
The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients. BMC Psychiatry (2010) 1.10
Neural substrates of olfactory processing in schizophrenia patients and their healthy relatives. Psychiatry Res (2007) 1.09
Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res (2010) 1.06
Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol (2008) 1.05
Immunohistochemical evidence for impaired neuregulin-1 signaling in the prefrontal cortex in schizophrenia and in unipolar depression. Ann N Y Acad Sci (2007) 1.05
Borderline personality disorder: a dysregulation of the endogenous opioid system? Psychol Rev (2010) 1.04
Dysfunctional long-term potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation. Behav Brain Res (2011) 1.04
Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system. Eur Arch Psychiatry Clin Neurosci (2011) 1.04
Health-related quality of life in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg (2007) 1.03
Volumes of association thalamic nuclei in schizophrenia: a postmortem study. Schizophr Res (2003) 1.03
A CAG repeat polymorphism of KCNN3 predicts SK3 channel function and cognitive performance in schizophrenia. EMBO Mol Med (2011) 1.00
Hippocampal deformities in the unaffected siblings of schizophrenia subjects. Biol Psychiatry (2003) 1.00
Is there a differential impact of fatigue and physical disability on quality of life in multiple sclerosis? J Nerv Ment Dis (2002) 0.99
Impulsive personality and the ability to resist immediate reward: an fMRI study examining interindividual differences in the neural mechanisms underlying self-control. Hum Brain Mapp (2011) 0.99
Articulatory rehearsal in verbal working memory: a possible neurocognitive endophenotype that differentiates between schizophrenia and schizoaffective disorder. Neurosci Lett (2006) 0.98
Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia. Schizophr Res (2006) 0.98
The dichotomy of schizophrenia and affective disorders in extended pedigrees. Schizophr Res (2002) 0.97
Proteome analysis of schizophrenia brain tissue. World J Biol Psychiatry (2010) 0.97
CACNA1C genotype explains interindividual differences in amygdala volume among patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci (2013) 0.94
Impaired long-term depression in schizophrenia: a cathodal tDCS pilot study. Brain Stimul (2011) 0.94
Tinnitus: distinguishing between subjectively perceived loudness and tinnitus-related distress. PLoS One (2012) 0.94
Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia. J Psychiatr Res (2010) 0.94
Reduced prefrontal gyrification in obsessive-compulsive disorder. Eur Arch Psychiatry Clin Neurosci (2010) 0.94
Effects of abstinence on brain morphology in alcoholism: a MRI study. Eur Arch Psychiatry Clin Neurosci (2009) 0.94
A novel mechanism and treatment target for presynaptic abnormalities in specific striatal regions in schizophrenia. Neuropsychopharmacology (2010) 0.94
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology. World J Biol Psychiatry (2015) 0.93
Reduction of the internal capsule in families affected with schizophrenia. Biol Psychiatry (2007) 0.93
Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. Eur Arch Psychiatry Clin Neurosci (2014) 0.93
The role of the cerebellum in schizophrenia: from cognition to molecular pathways. Clinics (Sao Paulo) (2011) 0.92
Structural synaptic elements are differentially regulated in superior temporal cortex of schizophrenia patients. Eur Arch Psychiatry Clin Neurosci (2012) 0.91
Familiality of obsessive-compulsive disorder in nonclinical and clinical subjects. Am J Psychiatry (2006) 0.91
Abnormal bihemispheric responses in schizophrenia patients following cathodal transcranial direct stimulation. Eur Arch Psychiatry Clin Neurosci (2012) 0.91
Cognitive impairment of executive function as a core symptom of schizophrenia. World J Biol Psychiatry (2009) 0.91
Compensatory hyperactivations as markers of latent working memory dysfunctions in patients with obsessive-compulsive disorder: an fMRI study. J Psychiatry Neurosci (2008) 0.91
Prefrontal cortex gyrification index in twins: an MRI study. Eur Arch Psychiatry Clin Neurosci (2011) 0.91
Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study. Acta Neuropathol (2012) 0.90
Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. Am J Psychiatry (2014) 0.90
Pathological amygdala activation during working memory performance: Evidence for a pathophysiological trait marker in bipolar affective disorder. Hum Brain Mapp (2010) 0.90
Genetic polymorphisms of 5-HTT and DAT but not COMT differentially affect verbal and visuospatial working memory functioning. Eur Arch Psychiatry Clin Neurosci (2012) 0.89
No change to grey and white matter volumes in bipolar I disorder patients. Eur Arch Psychiatry Clin Neurosci (2008) 0.89
Patients with schizophrenia show deficits of working memory maintenance components in circuit-specific tasks. Eur Arch Psychiatry Clin Neurosci (2010) 0.89
Functional brain abnormalities in psychiatric disorders: neural mechanisms to detect and resolve cognitive conflict and interference. Brain Res Rev (2008) 0.89
Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. J Neural Transm (Vienna) (2008) 0.89
Correlation between amygdala volume and age in bipolar disorder - a systematic review and meta-analysis of structural MRI studies. Psychiatry Res (2010) 0.88
Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS One (2013) 0.88
Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. World J Biol Psychiatry (2010) 0.88
SNAP-25 genotype influences NAA/Cho in left hippocampus. J Neural Transm (Vienna) (2008) 0.88
5-HTTLPR genotype influences amygdala volume. Eur Arch Psychiatry Clin Neurosci (2009) 0.88
Hippocampal integrity and neurocognition in first-episode schizophrenia: a multidimensional study. World J Biol Psychiatry (2011) 0.88
Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. Eur Arch Psychiatry Clin Neurosci (2012) 0.88
Antisaccade performance in patients with obsessive-compulsive disorder and unaffected relatives: further evidence for impaired response inhibition as a candidate endophenotype. Eur Arch Psychiatry Clin Neurosci (2012) 0.88
S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum. Eur Arch Psychiatry Clin Neurosci (2014) 0.87
Diagnosis-specific effect of familial loading on verbal working memory in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2009) 0.87
Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease. J Alzheimers Dis (2005) 0.87
Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies. Eur Arch Psychiatry Clin Neurosci (2008) 0.87
Increased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuse. Psychopharmacology (Berl) (2009) 0.86
Neuregulin-1 haplotype HAP(ICE) is associated with lower hippocampal volumes in schizophrenic patients and in non-affected family members. J Psychiatr Res (2008) 0.86
A functional neuroimaging study assessing gender differences in the neural mechanisms underlying the ability to resist impulsive desires. Brain Res (2012) 0.86
Differential expression of HINT1 in schizophrenia brain tissue. Eur Arch Psychiatry Clin Neurosci (2011) 0.86
Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci (2006) 0.86
Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study. World J Biol Psychiatry (2010) 0.85
Alterations in Event Related Potentials (ERP) associated with tinnitus distress and attention. Appl Psychophysiol Biofeedback (2008) 0.85
Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. J Neural Transm (Vienna) (2008) 0.85
Cerebrospinal fluid neurochemical phenotypes in vascular dementias: original data and mini-review. Dement Geriatr Cogn Disord (2008) 0.85
Muscle and timing-specific functional connectivity between the dorsolateral prefrontal cortex and the primary motor cortex. J Cogn Neurosci (2012) 0.85